Stargardt Disease clinical trials at University of California Health
3 in progress, 2 open to eligible people
Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease
open to eligible people ages 8-70
The purpose of this study is to determine the long term safety and tolerability of ALK-001 (C20-D3-retinyl acetate), and to explore the effects of ALK-001 on the progression of Stargardt disease in patients between the ages of 8 and 70 years old. Funding Source - FDA OOPD
at UCLA
Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1)
open to eligible people ages 18-60
To evaluate the safety and efficacy of Zimura™ (complement factor C5 inhibitor) compared to Sham in subjects with autosomal recessive Stargardt disease 1 (STGD1).
at UCLA
Safety and Efficacy of Emixustat in Stargardt Disease
Sorry, in progress, not accepting new patients
The purpose of this study is to determine if emixustat hydrochloride reduces the rate of progression of macular atrophy compared to placebo in subjects with Stargardt disease. Funding Source -- FDA OOPD
at UCSF
Our lead scientists for Stargardt Disease research studies include Michael Gorin, MD, PhD.
Last updated: